Healthcare
Tuesday, January 24, 2017
BRIEF-Ose Immunotherapeutics announces IDMC recommends continuation of pivotal Phase 3 clinical trial of Tedopi in non-small cell lung cancer
* Announces that the Independent Data Monitoring Committee (IDMC) recommends continuation of
pivotal Phase 3 clinical trial of Tedopi in non-small cell lung cancer
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment